← Browse by Condition
Medical Condition

mlh1 gene deletion duplication

Total Trials
1
Recruiting Now
1
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for mlh1 gene deletion duplication sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — mlh1 gene deletion duplication Clinical Trials

How many clinical trials are currently recruiting for mlh1 gene deletion duplication?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for mlh1 gene deletion duplication, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for mlh1 gene deletion duplication?
mlh1 gene deletion duplication research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a mlh1 gene deletion duplication clinical trial?
Eligibility criteria for mlh1 gene deletion duplication trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
San Raffaele University 1 trial

Recruiting Clinical Trials

NCT06708429
Recruiting
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Enrollment
300 pts
Location
United States, Italy
Sponsor
San Raffaele University
View Trial →

Related Conditions

lynch syndrome (1) lynch syndrome i (1) lynch syndrome ii (1) lynch syndrome i site specific colonic cancer (1) hnpcc (1) hnpcc gene mutation (1) hereditary cancer syndrome (1) hereditary cancer (1) mlh1 gene mutation (1) mlh1 loss of expression (1) mlh1 gene inactivation (1) msh2 gene mutation (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology